ARGUS/OVERWATCH
LATEST VERSION
DEVELOPING · 21 OCT → 29 OCT 2026 · 9 EDITIONS · 16 OUTLETS

Moderna-Merck personalized vaccine cuts melanoma recurrence or death risk by 42% in Phase 3 trial

How this story moved: how many newsrooms carried it at each run, when each one picked it up, how our summary's headline changed, and which figures and names held from the first reports to the latest. Everything here is counted from the coverage; none of it is a judgement of anyone's motives.

OUTLETS CARRYING THE STORY, RUN BY RUN

0 8 16 22 Oct 23 Oct 24 Oct 25 Oct 26 Oct 27 Oct 28 Oct 29 Oct 24 Oct 00:18 UTC · Moderna-Merck mRNA cancer vaccine lowers melanoma recurrence risk in Phase 3 trial 24 Oct 06:17 UTC · Moderna-Merck personalized vaccine cuts melanoma recurrence or death risk by 42% in Phase 3 trial

HOW OUR HEADLINE CHANGED · 2 HEADLINES

  1. 24 Oct, 00:18 UTC

    Moderna-Merck mRNA cancer vaccine lowers melanoma recurrence risk in Phase 3 trial

  2. 24 Oct, 06:17 UTC

    Moderna-Merck personalized vaccine cuts melanoma recurrence or death risk by 42% in Phase 3 trial

WHAT HELD, WHAT CAME LATER

From the first reports to the latest

  • Nothing ran from the first third of the coverage to the last.

Entered the story later

  • Hussein Tawbi · from 22 Oct 21:52, 2 outlets
  • European Society · from 22 Oct 21:52, 2 outlets
  • Medical Oncology · from 22 Oct 21:52, 2 outlets
  • 3 trial included · from 22 Oct 22:12, 2 outlets